Financhill
Back

Reshape Lifesciences Quote, Financials, Valuation and Earnings

#1 ETF for Monthly Dividend

Click HERE to learn more.
Sell
28

RSLS
Reshape Lifesciences

Last Price:
5.80
Seasonality Move:
24.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Beginner's Guide To Growing A Small Investment

Click here to download your free copy now!

Reshape Lifesciences Price Quote

$5.80
-0.08 (2.47%)
(Updated: November 2, 2024 at 6:41 AM ET)

Reshape Lifesciences Key Stats

Sell
28
Reshape Lifesciences (RSLS) is a Sell

Day range:
$5.40 - $5.99
52-week range:
$4.60 - $34.22
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.23
P/B ratio:
0.97%

Volume:
138.2K
Avg. volume:
398.7K
1-year change:
-60.6%
Market cap:
$3M
Revenue:
$8.7M
EPS:
$-72.06

How Much Does Reshape Lifesciences Make?

Is Reshape Lifesciences Growing As A Company?

  • What Is Reshape Lifesciences's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.13%
  • What Is Reshape Lifesciences's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Reshape Lifesciences Stock Price Performance

What Is Reshape Lifesciences 52-Week High & Low?

Reshape Lifesciences Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Reshape Lifesciences?

Is Reshape Lifesciences Cash Flow Positive?

  • What Is RSLS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$8.7M
  • What Is Reshape Lifesciences’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $5.1M
  • What Is Reshape Lifesciences’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Reshape Lifesciences Return On Invested Capital

  • Is Management Doing A Good Job?
    RSLS return on invested capital is -187.5%
  • What Is Reshape Lifesciences Return On Assets?
    ROA measures how assets are converting to revenues and is -100.3%
  • What Is RSLS Return On Equity?
    ROE is a measure of profitability and is -187.5%

Reshape Lifesciences Earnings Date & Stock Price

Reshape Lifesciences Competitors

Reshape Lifesciences Dividend Yield

Reshape Lifesciences Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 41%
Revenue: -12.82% -7.61%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 58.00
Upside from Last Price: 886.39%

Major Shareholders

  • How many RSLS shares are owned by institutional investors?
    1.2M RSLS shares are owned by institutional investors
  • How many RSLS shares are owned by insiders?
    2.9M RSLS shares are owned by insiders